Perrigo, nation's largest maker of generic over-the-counter medications, reported over $61 million in profit during its last quarter -- 60 percent higher than year ago.

Land seized in an eminent domain fight that reached the U.S. Supreme Court remains undeveloped, despite Pfizer's announcement that it was opening a new research center.

Drug maker said FDA will not approve potential Pompe disease treatment Lumizyme until the company fixes manufacturing problems at its Boston-area facility.

Drug maker is splitting off its holdings in infant formula maker Mead Johnson Nutrition Co. in order to focus on its biopharmaceutical business.

Federal health regulators found bits of steel, rubber and fiber in drugs made by Genzyme; second time this year the biotech company has been cited for contamination.

Analysis of studies testing possible new uses for an Pfizer Inc. epilepsy drug found reporting of results was often misleading, indicating it worked better than internal documents showed.

FDA agreed to consider developing rules for online advertising after companies complained that current guidelines for traditional media have left them hamstrung online.

Now that Pfizer plans to cut 600 jobs in Chesterfield, St. Louis County officials are rethinking $7 million in tax breaks promised to the company over the next decade.

U.S. Food and Drug Administration has finally approved GlaxoSmithKline's H1N1 vaccine -- the last of five manufacturers supplying vaccine to receive approval for its product.

Alder Biopharmaceuticals and Bristol-Myers Squibb signed a collaboration deal potentially worth $1 billion, with a key focus on a rheumatoid arthritis treatment.